Xap Therapeutics

Xap Therapeutics (formerly known as Rockend Ltd.) is a biotechnology company based in Cambridge, UK, established in 2017. The company has garnered significant attention from well-known US/UK blue-chip VCs, with the latest Venture Round investment led by Amplitude Ventures in January 2020. Xap Therapeutics stands out with its innovative approach to synthetic biology and cell therapeutics, employing CRISPR technology to engineer induced pluripotent stem cells (iPSCs) as the foundation for a universal cell platform. This platform aims to create a "chassis" cell that can be further functionalized into cell therapies, capable of processing external cues and releasing various types of cargos upon activation. The company's vision is to develop novel cell therapies with mechanisms of action beyond current approaches, offering a significant leap in the treatment of serious diseases such as autoimmunity and cancer. Xap Therapeutics is rapidly expanding its team, welcoming individuals from industry and academia to contribute to the development of the synthetic cell therapy platform and future clinical products. The company offers a dynamic and innovative working environment, positioning itself as an enticing career opportunity for talented individuals in the field of biotechnology and healthcare.